JP2013516456A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516456A5
JP2013516456A5 JP2012547587A JP2012547587A JP2013516456A5 JP 2013516456 A5 JP2013516456 A5 JP 2013516456A5 JP 2012547587 A JP2012547587 A JP 2012547587A JP 2012547587 A JP2012547587 A JP 2012547587A JP 2013516456 A5 JP2013516456 A5 JP 2013516456A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
viral
viral vector
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012547587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516456A (ja
JP6151515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000009 external-priority patent/WO2011083466A1/en
Publication of JP2013516456A publication Critical patent/JP2013516456A/ja
Publication of JP2013516456A5 publication Critical patent/JP2013516456A5/ja
Application granted granted Critical
Publication of JP6151515B2 publication Critical patent/JP6151515B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012547587A 2010-01-05 2011-01-05 神経膠芽腫gbmを治療するための組成物および方法 Expired - Fee Related JP6151515B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28222810P 2010-01-05 2010-01-05
US61/282,228 2010-01-05
US28224810P 2010-01-07 2010-01-07
US61/282,248 2010-01-07
PCT/IL2011/000009 WO2011083466A1 (en) 2010-01-05 2011-01-05 Compositions and methods for treating glioblastoma gbm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001588A Division JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫gbmを治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013516456A JP2013516456A (ja) 2013-05-13
JP2013516456A5 true JP2013516456A5 (enExample) 2014-02-20
JP6151515B2 JP6151515B2 (ja) 2017-06-21

Family

ID=44305240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012547587A Expired - Fee Related JP6151515B2 (ja) 2010-01-05 2011-01-05 神経膠芽腫gbmを治療するための組成物および方法
JP2016001588A Pending JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫gbmを治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016001588A Pending JP2016128440A (ja) 2010-01-05 2016-01-07 神経膠芽腫gbmを治療するための組成物および方法

Country Status (10)

Country Link
US (2) US20130209450A1 (enExample)
EP (1) EP2521777B1 (enExample)
JP (2) JP6151515B2 (enExample)
KR (1) KR101810257B1 (enExample)
AU (1) AU2011204407B2 (enExample)
CA (1) CA2786377C (enExample)
MX (1) MX338931B (enExample)
NZ (1) NZ601325A (enExample)
SG (2) SG10201500048SA (enExample)
WO (1) WO2011083466A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
CN102796741A (zh) 2006-07-31 2012-11-28 脉管生物生长有限公司 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用
CA2740726A1 (en) 2008-11-06 2010-05-14 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
US20130209450A1 (en) 2010-01-05 2013-08-15 Yael Cohen Compositions and Methods for Treating Glioblastoma GBM
AU2011204405B2 (en) 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
SI2908865T1 (sl) * 2012-10-17 2019-02-28 Vascular Biogenics Ltd. Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
EP3049151B1 (en) 2013-09-27 2019-12-25 Mevion Medical Systems, Inc. Particle beam scanning
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
JP6717825B2 (ja) 2014-11-26 2020-07-08 バスキュラー バイオジェニックス リミテッド 酸化脂質、および線維症の処置または予防方法
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
EP3481503B1 (en) 2016-07-08 2021-04-21 Mevion Medical Systems, Inc. Treatment planning
MX390145B (es) 2016-10-06 2025-03-20 Orbus Therapeutics Inc Formulaciones para la administracion de eflornitina
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
WO2019006253A1 (en) 2017-06-30 2019-01-03 Mevion Medical Systems, Inc. CONFIGURABLE COLLIMATOR CONTROLLED BY LINEAR MOTORS
US20210322574A1 (en) 2017-10-20 2021-10-21 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
US11291861B2 (en) 2019-03-08 2022-04-05 Mevion Medical Systems, Inc. Delivery of radiation by column and generating a treatment plan therefor
EP3937959A1 (en) 2019-03-13 2022-01-19 Vascular Biogenics Ltd. Methods of anti-tumor therapy
MX2021012398A (es) 2019-04-12 2021-11-12 Vascular Biogenics Ltd Metodos de terapia antitumoral.
US20220379010A1 (en) * 2021-05-19 2022-12-01 Alcyone Therapeutics, Inc. Fluid delivery systems and methods of treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
IL130608A0 (en) 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
KR100869814B1 (ko) 2000-11-17 2008-11-25 바스큘라 바이오제닉스 리미티드 내피세포 특이성을 나타내는 프로모터 및 이를 이용하는 방법
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
CA2575163A1 (en) 2004-08-09 2006-02-23 Merck & Co., Inc. Adenoviral vector compositions
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
CN102796741A (zh) 2006-07-31 2012-11-28 脉管生物生长有限公司 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用
US20130209450A1 (en) 2010-01-05 2013-08-15 Yael Cohen Compositions and Methods for Treating Glioblastoma GBM
AU2011204405B2 (en) 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
EP2523681A1 (en) 2010-01-12 2012-11-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
SI2908865T1 (sl) 2012-10-17 2019-02-28 Vascular Biogenics Ltd. Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka

Similar Documents

Publication Publication Date Title
JP2013516456A5 (enExample)
US12325756B2 (en) Use of trans-signaling approach in chimeric antigen receptors
Zhao et al. Oncolytic adenovirus: prospects for cancer immunotherapy
Xu et al. The role of CD40-CD154 interaction in cell immunoregulation
Zuo et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
JP2018509914A (ja) 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用
Gao et al. Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
Zuo et al. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
AU2021203142B2 (en) Anticancer Composition Comprising Recombinant Adenovirus Expressing Degradation Factor For Extracellular Matrix
CA3109216A1 (en) Recombinant myxoma viruses and uses thereof
JP2015524413A5 (enExample)
JP2021518126A (ja) 改変腫瘍溶解性アデノウイルス
AU2024227547A1 (en) Recombinant rhabdovirus encoding for CCL21
Zhang et al. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance
Wei et al. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
RU2016142370A (ru) Новые медицинские агенты и их применение
KR20230107666A (ko) 뇌종양 치료용 종양 용해성 단순 헤르페스 바이러스 1형
Kumar et al. TIME is critical for oncolytic viral therapies against solid cancers
Wu et al. A Universal Therapeutic Vaccine Leveraging Autologous Pre‐Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells
Singh Role of gene therapy in treatment of cancer for craniofacial regeneration—current molecular strategies, future perspectives, and challenges: a narrative review
WO2009009935A1 (fr) Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations
Liu et al. Liver Cancer Immune Microenvironment and Immunotherapy
Singh Journal of Yeungnam Medical Science
Khan et al. therapy: antigen selection